These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25266640)

  • 1. WHO 2010 classification of pancreatic endocrine tumors. is the new always better than the old?
    Ricci C; Casadei R; Taffurelli G; D'Ambra M; Monari F; Campana D; Tomassetti P; Santini D; Minni F
    Pancreatology; 2014; 14(6):539-41. PubMed ID: 25266640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
    Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
    Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Classification of pancreatic neuroendocrine tumours: Changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future].
    Scoazec JY; Couvelard A;
    Ann Pathol; 2017 Dec; 37(6):444-456. PubMed ID: 29169836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of WHO 2000 and WHO 2010 classifications of gastroenteropancreatic neuroendocrine tumors.
    Karakuş E; Helvacı A; Ekinci O; Dursun A
    Turk J Gastroenterol; 2014 Feb; 25(1):81-7. PubMed ID: 24918137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors.
    Liu TC; Hamilton N; Hawkins W; Gao F; Cao D
    Am J Surg Pathol; 2013 Jun; 37(6):853-9. PubMed ID: 23598967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the 2010 WHO classification and a new prognostic proposal: A single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours.
    Ricci C; Casadei R; Taffurelli G; Campana D; Ambrosini V; Pagano N; Santini D; De Giorgio R; Ingaldi C; Tomassetti P; Zani E; Minni F
    Pancreatology; 2016; 16(3):403-10. PubMed ID: 26924664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival following resection of pancreatic endocrine tumors: importance of R-status and the WHO and TNM classification systems.
    Pomianowska E; Gladhaug IP; Grzyb K; Røsok BI; Edwin B; Bergestuen DS; Mathisen O
    Scand J Gastroenterol; 2010 Aug; 45(7-8):971-9. PubMed ID: 20441530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.
    Farrell JM; Pang JC; Kim GE; Tabatabai ZL
    Cancer Cytopathol; 2014 Oct; 122(10):770-8. PubMed ID: 25044931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.
    Pape UF; Jann H; Müller-Nordhorn J; Bockelbrink A; Berndt U; Willich SN; Koch M; Röcken C; Rindi G; Wiedenmann B
    Cancer; 2008 Jul; 113(2):256-65. PubMed ID: 18506737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [WHO classification of pancreatic neuroendocrine tumor: overview].
    Sasano H; Yazdani S; Kasajima A
    Nihon Rinsho; 2015 Mar; 73 Suppl 3():321-6. PubMed ID: 25857041
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors: A Retrospective Nationwide Multicenter Study in South Korea.
    Cho JH; Ryu JK; Song SY; Hwang JH; Lee DK; Woo SM; Joo YE; Jeong S; Lee SO; Park BK; Cheon YK; Han J; Kim TN; Lee JK; Moon SH; Kim H; Park ET; Hwang JC; Kim TH; Jeon TJ; Cho CM; Choi HS; Lee WJ
    Pancreas; 2016 Aug; 45(7):941-6. PubMed ID: 26765964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms.
    Klöppel G
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S1-16. PubMed ID: 22005112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffusion-weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics.
    Wang Y; Chen ZE; Yaghmai V; Nikolaidis P; McCarthy RJ; Merrick L; Miller FH
    J Magn Reson Imaging; 2011 May; 33(5):1071-9. PubMed ID: 21509863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the World Health Organization 2010 grading system in surgical outcome and prognosis of pancreatic neuroendocrine tumors.
    Yang M; Tian BL; Zhang Y; Su AP; Yue PJ; Xu S; Wang L
    Pancreas; 2014 Oct; 43(7):1003-8. PubMed ID: 24945681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki-67 Index of 5% is Better Than 2% in Stratifying G1 and G2 of the World Health Organization Grading System in Pancreatic Neuroendocrine Tumors.
    Gao SW; Huang CS; Huang XT; Chen LH; Chen W; Cai JP; Yin XY
    Pancreas; 2019 Jul; 48(6):795-798. PubMed ID: 31210659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simple morphological classification to estimate the malignant potential of pancreatic neuroendocrine tumors.
    Oba A; Kudo A; Akahoshi K; Kishino M; Akashi T; Katsuta E; Iwao Y; Ono H; Mitsunori Y; Ban D; Tanaka S; Eishi Y; Tateishi U; Tanabe M
    J Gastroenterol; 2017 Oct; 52(10):1140-1146. PubMed ID: 28488114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.
    Strosberg JR; Cheema A; Weber JM; Ghayouri M; Han G; Hodul PJ; Kvols LK
    Ann Surg; 2012 Aug; 256(2):321-5. PubMed ID: 22415420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.